Open AccessTriple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
Author(s) -
Yoshimura Koji,
Muraoka Kei,
Fukasawa Michiko,
Fukushima Mika,
Kumagai Masatoshi,
Yabusaki Ryo,
Ueda Masakatsu,
Shiraishi Yusuke,
Imamura Masaaki
Publication year - 2022
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12457
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , radiation therapy , oncology , prostate , cancer , disease
Patients with nonmetastatic but exceptionally high‐risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen‐deprivation therapy, as first‐line treatment, may control the disease for a long period. Case presentation We treated a patient with super‐high‐risk, nonmetastatic prostate cancer, with triple combination therapy. He was biochemical relapse free at 60 months after the initiation of treatment. Conclusion Triple combination therapy may be an option for super‐high‐risk, nonmetastatic prostate cancer.